NYSEAMERICAN : OGEN
Oragenics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.374 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.69M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.69M |
| Enterprise Value | -2.18M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.51M |
| Shares Outstanding | 4.51M |
| Shares Change (YoY) | +714.58% |
| Shares Change (QoQ) | +2.97% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 1.50% |
| Float | 4.42M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.01 |
| Quick Ratio | 2.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -561.90 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,307.06% |
| Return on Assets (ROA) | -171.49% |
| Return on Invested Capital (ROIC) | -288.10% |
| Return on Capital Employed (ROCE) | -285.25% |
| Weighted Average Cost of Capital (WACC) | 11.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.36M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -205,912 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -71.01% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.61 |
| Relative Strength Index (RSI) | 31.06 |
| Average Volume (20 Days) | 21,550 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 836,995 |
| Short Previous Month | 806,542 |
| Short % of Shares Out | 18.55% |
| Short % of Float | 18.92% |
| Short Ratio (days to cover) | 29.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -3.42M |
| Operating Income | -10.47M |
| Pretax Income | -10.29M |
| Net Income | -10.08M |
| EBITDA | n/a |
| EBIT | -10.47M |
| Earnings Per Share (EPS) | -$2.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.86M |
| Total Debt | n/a |
| Net Cash | 3.86M |
| Net Cash Per Share | $0.86 |
| Equity (Book Value) | 3.67M |
| Book Value Per Share | 0.81 |
| Working Capital | 3.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.21M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -3.00M |
| Free Cash Flow | -10.21M |
| FCF Per Share | -$2.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -714.58% |
| Shareholder Yield | -714.58% |
| Earnings Yield | -671.69% |
| FCF Yield | -604.89% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |